Overview

Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion

Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
0
Participant gender:
All
Summary
This exploratory pilot study was an open-label, crossover, single-center and non-randomized clinical trial designed to compare the effect of the standardly employed doses of allopurinol (400 mg/day) and febuxostat (80 mg/day) on the urinary 2,8-dihydroxyadenine (DHA) excretion in patients with adenine phosphoribosyltransferase (APRT) deficiency.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Landspitali University Hospital
Collaborators:
Mayo Clinic
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Allopurinol
Febuxostat
Criteria
Inclusion Criteria:

- All patients 18 year and older who are enrolled in the APRT Deficiency Registry of The
Rare Kidney Stone Consortium.

Exclusion Criteria:

- Patients do not want to interrupt drug (allopurinol) treatment for a total of two
weeks as requested in protocol. No other exclusion criteria if inclusion criteria are
met.